mdm-2 expression in human testicular germ-cell tumors and its clinical value

Hanna Eid, Etel Institoris, L. Géczi, I. Bodrogi, M. Bak

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Background. In germ cell testicular tumors (GCTT) mdm-2 gene was analyzed for amplification and transcripts but not for protein. The purpose of this study is to determine whether mdm-2 protein level is aberrant in GCTT and if so, what is the relationship between mdm-2 overexpression and other disease parameters including histologic subtypes, p53 status, metastatic potential and clinical stage. Methods. 81 testicular germ-cell tumors were screened for their mdm-2 expression at the protein levels using immunohistochemistry (IHC) and Western blot (WB) analysis. Results. Of 81 GCTTs 45 (55.55%) showed mdm-2 nuclear immunoreactivity, 34 (41.97%) of which were strongly positive. The incidence of mdm-2 immunostaining was significantly higher (P = 0.0007) in non-seminomas (NSGCT) than in seminomas (SGCT). The frequency of positive tumor was higher in tumors from metastatic patients than in tumors from metastatic-free patients (P = 0.011). mdm-2 expression was detected significantly more frequently in tumors of advances stages, i.e. IIB, IIC and III versus tumors of early stages (I and II/A) (P = 0.0098). A significant difference between the three stages of disease as to the expression of mdm-2 (χ2 = 0.0386) could be established, namely the incidence of mdm-2 expression increased with an increase in stage. Using Western blotting 22 (68.75%) out of 32 tumors overexpressed the mdm-2 oncoprotein of 90 kd (p90). Conclusions. mdm-2 expression as detected by immunohistochemistry may provide a reliable prognostic tool to isolate subgroups of patients with more aggressive GCTT.

Original languageEnglish
Pages (from-to)3485-3490
Number of pages6
JournalAnticancer Research
Volume19
Issue number4 C
Publication statusPublished - 1999

Fingerprint

Neoplasms
Proto-Oncogene Proteins c-mdm2
Western Blotting
Immunohistochemistry
Seminoma
Oncogene Proteins
Incidence
Testicular Germ Cell Tumor
Proteins
Genes

Keywords

  • Immunohistochemistry
  • mdm-2 expression
  • Testicular tumors
  • Tumor progression
  • Western blotting

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

mdm-2 expression in human testicular germ-cell tumors and its clinical value. / Eid, Hanna; Institoris, Etel; Géczi, L.; Bodrogi, I.; Bak, M.

In: Anticancer Research, Vol. 19, No. 4 C, 1999, p. 3485-3490.

Research output: Contribution to journalArticle

@article{c99d90f05c464be29473c82a819e4ea5,
title = "mdm-2 expression in human testicular germ-cell tumors and its clinical value",
abstract = "Background. In germ cell testicular tumors (GCTT) mdm-2 gene was analyzed for amplification and transcripts but not for protein. The purpose of this study is to determine whether mdm-2 protein level is aberrant in GCTT and if so, what is the relationship between mdm-2 overexpression and other disease parameters including histologic subtypes, p53 status, metastatic potential and clinical stage. Methods. 81 testicular germ-cell tumors were screened for their mdm-2 expression at the protein levels using immunohistochemistry (IHC) and Western blot (WB) analysis. Results. Of 81 GCTTs 45 (55.55{\%}) showed mdm-2 nuclear immunoreactivity, 34 (41.97{\%}) of which were strongly positive. The incidence of mdm-2 immunostaining was significantly higher (P = 0.0007) in non-seminomas (NSGCT) than in seminomas (SGCT). The frequency of positive tumor was higher in tumors from metastatic patients than in tumors from metastatic-free patients (P = 0.011). mdm-2 expression was detected significantly more frequently in tumors of advances stages, i.e. IIB, IIC and III versus tumors of early stages (I and II/A) (P = 0.0098). A significant difference between the three stages of disease as to the expression of mdm-2 (χ2 = 0.0386) could be established, namely the incidence of mdm-2 expression increased with an increase in stage. Using Western blotting 22 (68.75{\%}) out of 32 tumors overexpressed the mdm-2 oncoprotein of 90 kd (p90). Conclusions. mdm-2 expression as detected by immunohistochemistry may provide a reliable prognostic tool to isolate subgroups of patients with more aggressive GCTT.",
keywords = "Immunohistochemistry, mdm-2 expression, Testicular tumors, Tumor progression, Western blotting",
author = "Hanna Eid and Etel Institoris and L. G{\'e}czi and I. Bodrogi and M. Bak",
year = "1999",
language = "English",
volume = "19",
pages = "3485--3490",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "4 C",

}

TY - JOUR

T1 - mdm-2 expression in human testicular germ-cell tumors and its clinical value

AU - Eid, Hanna

AU - Institoris, Etel

AU - Géczi, L.

AU - Bodrogi, I.

AU - Bak, M.

PY - 1999

Y1 - 1999

N2 - Background. In germ cell testicular tumors (GCTT) mdm-2 gene was analyzed for amplification and transcripts but not for protein. The purpose of this study is to determine whether mdm-2 protein level is aberrant in GCTT and if so, what is the relationship between mdm-2 overexpression and other disease parameters including histologic subtypes, p53 status, metastatic potential and clinical stage. Methods. 81 testicular germ-cell tumors were screened for their mdm-2 expression at the protein levels using immunohistochemistry (IHC) and Western blot (WB) analysis. Results. Of 81 GCTTs 45 (55.55%) showed mdm-2 nuclear immunoreactivity, 34 (41.97%) of which were strongly positive. The incidence of mdm-2 immunostaining was significantly higher (P = 0.0007) in non-seminomas (NSGCT) than in seminomas (SGCT). The frequency of positive tumor was higher in tumors from metastatic patients than in tumors from metastatic-free patients (P = 0.011). mdm-2 expression was detected significantly more frequently in tumors of advances stages, i.e. IIB, IIC and III versus tumors of early stages (I and II/A) (P = 0.0098). A significant difference between the three stages of disease as to the expression of mdm-2 (χ2 = 0.0386) could be established, namely the incidence of mdm-2 expression increased with an increase in stage. Using Western blotting 22 (68.75%) out of 32 tumors overexpressed the mdm-2 oncoprotein of 90 kd (p90). Conclusions. mdm-2 expression as detected by immunohistochemistry may provide a reliable prognostic tool to isolate subgroups of patients with more aggressive GCTT.

AB - Background. In germ cell testicular tumors (GCTT) mdm-2 gene was analyzed for amplification and transcripts but not for protein. The purpose of this study is to determine whether mdm-2 protein level is aberrant in GCTT and if so, what is the relationship between mdm-2 overexpression and other disease parameters including histologic subtypes, p53 status, metastatic potential and clinical stage. Methods. 81 testicular germ-cell tumors were screened for their mdm-2 expression at the protein levels using immunohistochemistry (IHC) and Western blot (WB) analysis. Results. Of 81 GCTTs 45 (55.55%) showed mdm-2 nuclear immunoreactivity, 34 (41.97%) of which were strongly positive. The incidence of mdm-2 immunostaining was significantly higher (P = 0.0007) in non-seminomas (NSGCT) than in seminomas (SGCT). The frequency of positive tumor was higher in tumors from metastatic patients than in tumors from metastatic-free patients (P = 0.011). mdm-2 expression was detected significantly more frequently in tumors of advances stages, i.e. IIB, IIC and III versus tumors of early stages (I and II/A) (P = 0.0098). A significant difference between the three stages of disease as to the expression of mdm-2 (χ2 = 0.0386) could be established, namely the incidence of mdm-2 expression increased with an increase in stage. Using Western blotting 22 (68.75%) out of 32 tumors overexpressed the mdm-2 oncoprotein of 90 kd (p90). Conclusions. mdm-2 expression as detected by immunohistochemistry may provide a reliable prognostic tool to isolate subgroups of patients with more aggressive GCTT.

KW - Immunohistochemistry

KW - mdm-2 expression

KW - Testicular tumors

KW - Tumor progression

KW - Western blotting

UR - http://www.scopus.com/inward/record.url?scp=0033452513&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033452513&partnerID=8YFLogxK

M3 - Article

C2 - 10629640

AN - SCOPUS:0033452513

VL - 19

SP - 3485

EP - 3490

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 4 C

ER -